Introduction
============

Ocular surface squamous neoplasia (OSSN) is the most common ocular surface tumour (Grossniklaus *et al*. [@b35]). Other synonymous terms include 'conjunctival epithelial neoplasia', 'ocular surface epithelial dysplasia' and 'conjunctival squamous cell neoplasia' (Lee & Hirst [@b54]; McDonnell *et al*. [@b69]; Tulvatana [@b112]). OSSN covers a spectrum of disease ranging from non-invasive intra-epithelial dysplasia of the conjunctiva and cornea (CCIN) to invasive squamous cell carcinoma (Lee & Hirst [@b55]).

Clinical features
-----------------

The disease may present with irritation, red eye, raised gelatinous mass and leucoplakia (Tunc *et al*. [@b113]). In Africans, it is often pigmented brown (Figure[1](#fig01){ref-type="fig"}). OSSN is usually unilateral (Chisi *et al*. [@b14]) and arises at the limbus -- the junction between the cornea and conjunctiva (Lee & Hirst [@b56]). Most lesions occur within the exposed part of the eyeball between the lids (Ateenyi-Agaba [@b3]; McKelvie [@b70]; Waddell *et al*. [@b123]). Up to 31.2% of cases seen are recurrent lesions (Chisi *et al*. [@b14]). Late stages present with a large fungating oculo-orbital mass (Ogun *et al*. [@b82]). Early lesions resemble benign growths such as pterygia and pingueculae. OSSN can be the first manifestation of HIV infection in about 50% of cases in HIV-endemic settings (Porges & Groisman [@b89]; Spitzer *et al*. [@b100]).

![A range of clinical presentations of ocular surface squamous neoplasia (OSSN) in East Africa. (a) Small lesion with leukoplakia; (b) Medium sized lesion with pigmentation; (c) Large lesion with corneal extension but not involving the fornices; (d) Very large lesion extending into the orbit.](tmi0018-1424-f1){#fig01}

Histopathology
--------------

Histologically, OSSN may be classified into 3 forms: benign, pre-invasive and invasive (Table [1](#tbl1){ref-type="table"}; Basti & Macsai [@b9]). The term OSSN usually excludes the benign forms. The term 'invasive' indicates infiltration through the basement membrane of the conjunctival epithelium into the underlying stroma (Basti & Macsai [@b9]; Shields & Shields [@b97]).

###### 

Histopathological classification of ocular surface squamous neoplasia (OSSN), Basti & Macsai ([@b9]) and American Joint Committee on Cancer ([@b2])

  ---------------------------------------------------------------------------------------------------
  Benign
   Squamous papilloma
   Pseudoepitheliomatous hyperplasia
   Benign hereditary intraepithelial dyskeratosis
  Pre-invasive
   Conjunctival intraepithelial neoplasia (CIN)
    CIN I (mild dysplasia) -- confined to the basal third of the conjunctival epithelium
    CIN II (moderate dysplasia) -- extends into the middle third of the conjunctival epithelium
    CIN III (severe dysplasia) -- extends into the superficial third of the conjunctival epithelium
    CIS (carcinoma-*in-situ*) -- full thickness dysplasia[\*](#tf1-1){ref-type="table-fn"}
  Invasive
   Squamous cell carcinoma
    GX -- grade cannot be defined
    G1 -- Well differentiated
    G2 -- Moderately differentiated
    G3 -- Poorly differentiated
    G4 -- undifferentiated
   Mucoepidermoid carcinoma
  ---------------------------------------------------------------------------------------------------

The American Joint Committee on Cancer (AJCC) staging manual 2010 classifies CIS under CIN.

Epidemiology overview
---------------------

Two disease patterns of OSSN are recognised: older, predominantly male in temperate climates, not associated with HIV or human papilloma virus (HPV); and younger men and women, in tropical climates, associated with HIV and HPV. The latter represents a public health challenge in Africa in relation to the HIV pandemic and late presentation of large tumours (Ukponmwan *et al*. [@b115]; Chisi *et al*. [@b14]; Ogun *et al*. [@b82]), diagnostic difficulties (Furahini & Lewallen [@b31]), malignant transformation and high recurrence rates after treatment (1-year recurrence of 16.6% reported in Tanzania; Makupa *et al*. [@b61]). Experienced surgeons report lower recurrences (3.2%) after excision (Waddell *et al*. [@b123]). Trial data to guide management in this context are lacking (Gichuhi & Irlam [@b32]). For the temperate pattern of disease, one randomised controlled crossover trial in Australia compared mitomycin-C with placebo in participants whose average age was 67 years (Hirst [@b42]). There was a significant treatment effect on clinically assessed complete resolution of lesions (*P* = 0.0005), but no effect on histologically assessed complete resolution (*P* = 0.49).

Incidence rates and geographical variation
------------------------------------------

Incidence estimates for OSSN are difficult to ascertain and vary regionally (Table [2](#tbl2){ref-type="table"}). The first paper to examine this used cancer registry data from International Agency for Research on Cancer (IARC; Newton *et al*. [@b77]). A subset of these data were used in a subsequent publication looking at variation in incidence across the USA (Emmanuel *et al*. [@b28]). However, published results need to be interpreted with caution -- firstly, all eye cancers are classified together by the International Classification of Diseases for Oncology (ICD-O-3 C.69) while other databases classify squamous cell carcinoma of the conjunctiva (SCCC) with head and neck cancers (Lee *et al*. [@b58]; Curado *et al*. [@b19]; Parkin *et al*. [@b84]). OSSN is not recognised as a separate entity. Squamous cell carcinomas that are site-coded for the eye (C69) probably include some cancers that originate in the eyelid skin (WHO [@b125], [@b126]; Curado *et al*. [@b19]). Secondly, the availability of histopathology services to confirm OSSN diagnosis is often limited in low- and middle-income countries (Furahini & Lewallen [@b31]). Thirdly, health information systems tend to capture invasive squamous cell carcinoma (SCC) but not earlier stages. Countries reporting higher rates of SCC (mostly in Africa) only started sending cancer registry data to IARC in the mid-1980s (Curado *et al*. [@b19]). Completeness of the current IARC database is hampered in that only data from 80 countries were submitted, of which 75% was of acceptable quality, and not all countries had data on squamous cell carcinoma in the eye under code C69. Africa had the lowest level of acceptable quality of data (36%). Fourthly, crude incidence rates can be influenced by population structure, a problem often addressed by reporting age-standardised incidence rates. Finally, in areas with limited health facilities for cancer treatment where a large number of patients are treated outside the reference area, incidence may be underestimated. Moreover, in defining incidence from different sources, it may be difficult to distinguish between recurrence or extension of an existing cancer on one hand and the development of a new primary on the other. Analysis of incidence time trends is also difficult if geographical coverage, ICD revisions and disease definitions in a registry change.

###### 

Age-standardized incidence rates of squamous cell carcinoma in the eye (ICD-O-3 C.69) by continent for the period 1998--2002 (Curado *et al*. [@b19])

                            Age-standardized incidence rate (cases/year/100 000 pop)                          
  ------------------------- ---------------------------------------------------------- ---------------------- ---------
  Africa                    1.38 (−1.00 to 3.75)                                       1.18 (−1.08 to 3.43)   0.853
  Central & South America   0.48 (0.33 to 0.62)                                        0.21 (0.10 to 0.33)    0.005
  Oceania                   0.28 (0.14 to 0.41)                                        0.05 (0.01 to 0.10)    0.002
  North America             0.08 (0.06 to 0.10)                                        0.00 (0.00 to 0.01)    \<0.001
  Asia                      0.08 (0.01 to 0.14)                                        0.05 (0.00 to 0.09)    0.416
  Europe                    0.05 (0.02 to 0.08)                                        0.01 (0.00 to 0.03)    0.033
  Southern Hemisphere       0.61 (0.14 to 1.09)                                        0.33 (−0.12 to 0.78)   0.355
  Northern Hemisphere       0.10 (0.06 to 0.14)                                        0.05 (0.00 to 0.08)    0.045
  Worldwide estimate        0.18 (0.09 to 0.26)                                        0.08 (0.01 to 0.15)    0.091

CI = confidence interval.

Methods for this review
=======================

Systematic and non-systematic review methods were used. No *a priori* systematic review protocol had been published. Incidence data were obtained from the current IARC report (9th Volume) covering the period 1998--2002. The IARC collates data from cancer registries worldwide. The report uses ICD codes to show the age-standardised incidence per 100 000 population stratified by sex and histological type. Under code C.69 where eye cancers are reported, the four main groups are retinoblastoma, malignant melanoma, carcinomas (11.4% of all eye cancers), sarcoma and other unspecified tumours. Under carcinomas, there are three subgroups -- SCC (principally tumours of the conjunctiva and cornea, comprising 70% of the carcinoma subgroup), other specified carcinoma (adenocarcinomas of the lacrimal gland and lacrimal duct) and unspecified carcinomas. We extracted data from the SCC subgroup. The coordinates locating each registry were obtained from <http://itouchmap.com/latlong.html>.

We searched PubMed, EMBASE and Web of Science for systematic reviews, meta-analysis and case--control studies using 'OSSN', 'conjunctival squamous cell carcinoma', 'risk factors' and their synonyms as key words with no language restrictions. Abstracts were assessed and studies were selected if they reported analysis of known or suspected risk factors. The search was conducted on 2 January 2013 and updated on 31 May 2013. Data were extracted from the full texts of articles and additional articles obtained from their reference lists. Meta-analyses were conducted where appropriate. A fixed-effects model was used for HIV and cigarette smoking. A random-effects model was chosen for HPV after investigation of heterogeneity.

Results and discussion
======================

Africa has the highest age-standardised incidence rate of ocular SCC followed by Central and South America then Oceania (Australia, New Zealand and Hawaii), respectively (Table [2](#tbl2){ref-type="table"} and [Figure 2](#fig02){ref-type="fig"}). The rate in Africa is about 9--10 times higher than in Europe and North America. The highest incidence rate is 3.4 cases/year/100 000 among males and 3.0 cases/year/100 000 among females in Zimbabwe (Curado *et al*. [@b19]). Uganda follows with 1.6 cases/year/100 000 for males and females. Australia comes third with 0.3--0.5 cases/year/100 000 in parts of that country. Other countries have rates between 0 and 0.1 cases/year/100 000. The rates have a right-skewed bell-shaped distribution peaking at latitude 16° South (Figure[3](#fig03){ref-type="fig"}). Incidence rates are higher in the Southern Hemisphere than the Northern Hemisphere, with male ASR = 0.61 cases/year/100 000 (95% CI: 0.14--1.09) and female ASR = 0.33 (95% CI: −0.12 to 0.78) in the Southern Hemisphere, compared with male ASR = 0.10 (95% CI: 0.06--0.14) and female ASR = 0.05 (95% CI: 0.00--0.08) in the Northern Hemisphere.

![Worldwide mapping of the age-standardized incidence rates (ASR) of squamous cell carcinoma of the eye (ICD-O-3 C.69) for the period 1998--2002 (Curado *et al*. [@b19]). Key: Dot size is directly proportional to incidence. Males are shown in blue and females in red. Overlaps between males and females appear purple in colour.](tmi0018-1424-f2){#fig02}

![The age-standardized incidence rates (ASR) of squamous cell carcinoma of the eye (ICD-O-3 C.69) for the period 1998--2002 (Curado *et al*. [@b19]).](tmi0018-1424-f3){#fig03}

The high rates in Africa are consistent with other estimates from the region. A Tanzanian study estimated the incidence of suspected OSSN from 2006 to 2008 using operating theatre records across the country. Although there was no histological confirmation in all cases, the incidence was found to be 2.2 cases/year/100 000 (Furahini & Lewallen [@b31]). Uganda reported a peak incidence of 3.5 cases/year/100 000 in 1992 (Ateenyi-Agaba [@b3]). More recent data from the Kampala Cancer Registry also show a marked increase, although it is reported as ocular cancer, rather than specifically as OSSN (Wabinga *et al*. [@b120]).

Cancer registry data in two African countries show that OSSN has become more prevalent with time. In Zimbabwe, the age-adjusted annual incidence rates of SCCC underwent a more than 10-fold increase from 0.17 to 1.8/100 000 between 1990 and 1999 (Masanganise *et al*. [@b67]) while the prevalence of OSSN among ocular surface tumour biopsy specimens increased from 33% in 1996 to 58% by 2000 (Pola *et al*. [@b87]).

OSSN is the most common indication for orbital exenteration performed in adults in Africa (Table [3](#tbl3){ref-type="table"}). This surgical procedure to excise all the orbital tissue including stripping the periosteum from the orbital walls is performed in cases with advanced disease. More than half (≥57%) the exenterations performed in Africa are for OSSN compared with 32% in Australia and 9--15% in Europe and India. Although available data does not clearly distinguish those performed for primary eyelid disease from conjunctival disease, SCC still emerges as an important cause in Africa. Eyelid SCC is uncommon in Africa (Templeton [@b105], [@b106]).

###### 

The proportion of orbital exenterations performed due to ocular squamous cell carcinoma in different regions of the world

  Year (ref.)                          Country                                  No. of exenterations (*N*)   No. due to SCCC (*n*)   Proportion (*n*/*N*) (%)
  ------------------------------------ ---------------------------------------- ---------------------------- ----------------------- --------------------------
  2011 (Ackuaku-Dogbe [@b1])           Ghana                                    25                           19                      76
  2001 (Masanganise & Magava [@b66])   Zimbabwe                                 23                           13                      57
  2007 (Nemet *et al*. [@b76])         Australia                                38                           12                      32
  2004 (Pushker *et al*. [@b90])       India                                    26                           3                       15
  2008 (Croce *et al*. [@b18])         Italy[\*](#tf3-1){ref-type="table-fn"}   6                            1                       13
  2005 (Rahman *et al*. [@b91])        UK[†](#tf3-2){ref-type="table-fn"}       69                           6                       9

Included children.

Mainly elderly patients.

Incidence of OSSN by age and sex
--------------------------------

In temperate countries, OSSN remains a rare, slow-growing tumour of elderly males (70--80% are males with a mean age of about 60 years; Lee & Hirst [@b56]; Tunc *et al*. [@b113]). In contrast, in tropical countries, particularly in Eastern and Southern Africa, the prevalence is highest among young people in their 30s and among women (50--70%; Table [4](#tbl4){ref-type="table"}; Poole [@b88]; Pola *et al*. [@b87]; Chisi *et al*. [@b14]; Furahini & Lewallen [@b31]). Within East Africa, the pattern of SCCC in the 1960s differed to that seen today. In 1967, the average age of affected patients was 48 years, and males were four times more frequently affected than females (Templeton [@b105]).

###### 

The age and sex of patients affected by ocular surface squamous neoplasia (OSSN)

  Year (ref.)                       Country     Mean age (years)   Male (%)   Female (%)   Male:Female ratio
  --------------------------------- ----------- ------------------ ---------- ------------ -------------------
  1995 (Ateenyi-Agaba [@b3])        Uganda      33                 52         48           1:2.3
  2008 (Spitzer *et al*. [@b100])   Malawi      33                 42         58           1:2.1
  2010 (Simbiri *et al*. [@b98])    Botswana    39                 39         61           1:1.6
  2003 (Pola *et al*. [@b87])       Zimbabwe    35                 30         70           1:1.4
  2002 (Mahomed & Chetty [@b60])    S. Africa   37                 50         50           1:1.3
  2006 (Chisi *et al*. [@b14])      Kenya       38                 50         50           1:1
  2012 (Makupa *et al*. [@b61])     Tanzania    39                 32         68           1:1
  2009 (Ogun *et al*. [@b82])       Nigeria     54                 43         57           1:0.9
  1999 (Tunc *et al*. [@b113])      USA         64                 70         30           1:0.4
  2002 (McKelvie [@b70])            Australia   69                 77         23           1:0.3

Worldwide, IARC data show that the overall incidence is higher in males than females but the difference is not statistically significant (Figure[3](#fig03){ref-type="fig"} and Table [2](#tbl2){ref-type="table"}). The mean male ASR worldwide is 0.18 cases/year/100 000 (95% CI: 0.09--0.26) and 0.08 (95% CI: 0.01--0.15) among females (*P* = 0.09). Incidence is significantly higher in males than females except in Africa and Asia where both sexes are equally affected (Table [2](#tbl2){ref-type="table"}). Prevalence in Africa is higher in females than males (Table [4](#tbl4){ref-type="table"}). This may be related to Africa having the highest prevalence of both HIV and HPV, which may increase the risk of OSSN in women and gender differences in mortality of HIV-infected adults. In South Africa, HIV-infected females have a longer life expectancy than HIV-infected males (Cornell *et al*. [@b17]; Johnson *et al*. [@b46]; Maskew *et al*. [@b68]). Men present in later stages of HIV/AIDS for antiretroviral therapy (ART) and possibly have poorer adherence to ART (Taylor-Smith *et al*. [@b104]). This has also been observed in Latin America, China and Lao (Dou *et al*. [@b25]; Gonzalez *et al*. [@b34]; Bastard *et al*. [@b8]). In Europe, the response to ART and mortality is similar for both sexes (Perez-Molina *et al*. [@b85]; Thorsteinsson *et al*. [@b107]).

Variation in disease severity
-----------------------------

There may be variation in disease stage at presentation, with more advanced disease present at time of surgery in East Africa, compared with other regions (Table [5](#tbl5){ref-type="table"}; Chisi *et al*. [@b14]; Waddell *et al*. [@b124]; Kao *et al*. [@b48]; Makupa *et al*. [@b61]). This may reflect delayed presentation to ophthalmic services in this region, leading to more advanced pathology by the time of surgery. Histopathological reporting is also subjective, and pathologists may not always grade tumours the same way (Margo *et al*. [@b65]). Alternatively, the disease may be intrinsically more aggressive in the East African region or HIV worsens disease progression.

###### 

Stages of ocular surface squamous neoplasia (OSSN) seen at presentation in Africa and USA

                                               Stage of OSSN, *n* (%)                                                                
  -------------------------------------------- ------------------------ ----------- ----------- ------------ ------------ ---------- -----------
  Kenya 2006 (Chisi *et al*. [@b14])           7 (21.9)                                                      1 (3.1)      9 (28.1)   15 (46.9)
  Uganda 2008 (de Koning *et al*. [@b20])      17 (21.0)                18 (22.2)   22 (27.2)   0 (0)        24 (29.6)               
  Uganda 2010 (Ateenyi-Agaba *et al*. [@b6])   39 (29.3)                                                     94 (70.7)               
  Uganda 2010 (Waddell *et al*. [@b124])       48 (15.1)                66 (20.8)   81 (25.5)   0 (0)        123 (38.7)              
  Tanzania 2012 (Makupa *et al*. [@b61])       28 (21.2)                            73 (55.3)   0 (0)        31 (23.5)               
  Malawi 2013 (Tiong *et al*. [@b108])         1 (2.0)                  5 (10.2)    9 (18.4)    17 (34.7)    17 (34.7)               
  USA 2012 (Kao *et al*. [@b48])               48 (8.1)                 98 (16.4)   59 (9.9)    322 (54.0)   69 (11.6)               

Risk factors
------------

Various factors are thought to influence the causation of OSSN, but it is not clear how they interact or which is the most potent. The rising incidence of OSSN in recent decades may be driven by increased prevalence of these factors. We found no systematic reviews of risk factors for OSSN after the literature search. Of the case--control studies found, two in Uganda and Australia examined the association with solar exposure; six in Africa examined the association with HIV; sixteen examined the association with HPV; seven in Africa, five in Asia, one in Brazil, two in USA and one in Australia. Two studies examined cigarette smoking in Uganda.

### Ultraviolet solar radiation

Several cutaneous malignancies, including melanoma and SCC, have a strong association with solar radiation. It was first noted in the 1960s that SCCC was relatively common in East Africa, and this apparent excess risk was attributed to higher exposure to sunlight (Templeton [@b105]). There is a strong relationship between the incidence of SCCC and increasing Ultraviolet (UV) levels (Newton *et al*. [@b77]). Using IARC data and published measurements of ambient solar ultraviolet light, the incidence of SCCC was found to reduce by 49% for every 10° increase in latitude from 1.2 cases/year/100 000 (Table [7](#tbl7){ref-type="table"}) in Uganda (latitude 0.3°) to \<0.02/year/100 000 in the UK (latitude \> 50°). More recently, the National Institutes of Health/American Association of Retired Persons (NIH-AARP) Diet and Health Study in the USA found a slightly lower risk of SCCC in those who lived \>35° compared with ≤35° from the equator, although this was not statistically significant (adjusted Hazard Ratio = 0.92, 95% CI: 0.49--1.71; Emmanuel *et al*. [@b28]). The USA has comparatively lower HIV prevalence, solar irradiance and incidence of OSSN than Africa, which is bisected by the equator. The high incidence of ocular SCC near the equator may be related to high solar irradiance (the amount of solar radiant energy incident on a surface per unit area and per unit time) in the world (World Energy Council [@b127]).

A case--control study in Uganda adjusted for age, sex, residential district, and HIV serostatus demonstrated that the risk of OSSN was higher with increasing time spent in daylight (Waddell *et al*. [@b124]). Compared with those who reported spending up to 1 h a day in direct sunlight, the odds ratio (OR) for those who spent 2--4 h was 1.7 (95% CI: 1.2--2.4), and for those who spent 5 or more hours a day, it was 1.8 (95% CI: 1.1--3.1). A case--control study in Australia reported that the strongest risk factor was a past history of skin cancer (OR = 15, 95% CI: 2.0--113.6), although other factors, including outdoor activity, pale skin and irides and propensity to burn, were also important (Lee *et al*. [@b57]).

More direct evidence for UV radiation induced damage in the pathophysiology of SCCC was described in another case--control study in Uganda in which 52% of the cases had mutations in the tumour suppressor gene TP53 compared with 14% of controls (Ateenyi-Agaba *et al*. [@b4]). The mutations were mainly of the CC TT type, consistent with UV-induced mutagenesis. This gene also downregulates the replication of HPV type 16 via the viral E2 protein, suggesting that its mutation may allow replication of HPV particles (Brown *et al*. [@b12]). Further, exposure to UV radiation is associated with altered expression of matrix metalloproteinases (MMPs) and the tissue inhibitors of these metalloproteinases (TIMPs), molecules that may be responsible for tissue invasion and metastasis of tumours (Ng *et al*. [@b80]).

In addition, OSSN lesions occur more often at the limbus. A study in Uganda demonstrated that tumours almost always occur in sun-exposed areas of the eye (Waddell *et al*. [@b123]). It is thought that the human eye is more exposed laterally, making this a large collecting zone of peripheral sunlight, which, depending on the incident angle and radius of curvature of the cornea, is focused on the limbus, lens and lid margin, which are the main foci of sun-related eye diseases such as pterygium, OSSN, cataract and lid malignancies (Maloof *et al*. [@b62]). Low doses of ambient sunlight received on every day exposure inhibit immunity in the skin and internal organs (Halliday *et al*. [@b39]).

### HIV

There is strong evidence that HIV is a major risk factor for OSSN. Uganda, which had a cancer registry since 1951, was the first country to report a dramatic increase in the annual incidence of SCCC shortly after the outbreak of HIV/AIDS. There was a sixfold increase from 0.6 cases/year/100 000 between 1970 and 1988 to 3.5/year/100 000 by 1992 (Figure[4](#fig04){ref-type="fig"}; Ateenyi-Agaba [@b3]). A marked rise was also observed in the USA with the onset of the HIV pandemic (Guech-Ongey *et al*. [@b36]). At the same time, a US study observed a strong association in an HIV-infected cohort (OR = 13.0, 95% CI: 4--34; Goedert & Cote [@b33]). In Tanzania, regional incidence rates were significantly correlated with regional HIV prevalence (Pearson\'s *r* = 0.53, *P* = 0.03; Furahini & Lewallen [@b31]). The majority of patients (60--77%) with OSSN seen in Africa are HIV-infected (Table [6](#tbl6){ref-type="table"}). A meta-analysis of 6 case--control studies (Table [7](#tbl7){ref-type="table"}) in Uganda, Rwanda and Zimbabwe shows a strong association with HIV infection (pooled OR = 6.17, 95% CI: 4.83--7.89; Figure[5](#fig05){ref-type="fig"}).

![Sudden rise in the annual incidence rates of conjunctival SCCC in Kampala with the onset of the HIV pandemic -- number of cases shown (Ateenyi-Agaba [@b3]).](tmi0018-1424-f4){#fig04}

![Meta-analysis of case-control studies of HIV infection in ocular surface squamous neoplasia (OSSN) in Africa (fixed effect).](tmi0018-1424-f5){#fig05}

###### 

Prevalence of HIV infection in cases of squamous cell carcinoma of the conjunctiva in Africa

  Year (ref.)                       Country        Study period   HIV prevalence in SCCC cases (%)
  --------------------------------- -------------- -------------- ----------------------------------
  2012 (Makupa *et al*. [@b61])     Tanzania       2005--2008     60
  2011 (Osahon *et al*. [@b83])     Nigeria        1999--2009     75
  2002 (Mahomed & Chetty [@b60])    South Africa   1995--1997     71
  1995 (Ateenyi-Agaba [@b3])        Uganda         1990--1991     75
  1996 (Waddell *et al*. [@b121])   Uganda         1993--1994     71
  2003 (Porges & Groisman [@b89])   Zimbabwe       1993--1995     91
  2001 (Newton *et al*. [@b78])     Uganda         1994--1998     77

The association with HIV suggests that immunosuppression plays a role in OSSN; however, a linear association between the CD4 lymphocyte count and OSSN has not been confirmed. A cross-sectional study conducted in Tanzania found a median CD4 cell count of 71 cells/μl among HIV-infected individuals with OSSN (Makupa *et al*. [@b61]). HIV-infected cases tended to have larger lesions: 71% had lesions \>5 mm in diameter *vs*. 27% among HIV-negative individuals (OR = 3.13, 95% CI: 1.5--6.5). HIV-infected cases were also more likely to develop recurrent tumours within a year of excision (82% *vs*. 18%; OR = 3.54, 95% CI: 1.12--11.2). However, there was no significant trend found between CD4 count and the grade of OSSN (*P* = 0.94). In a Ugandan study, among 112 HIV-infected cases of CIN and invasive SCC, the median CD4 count at diagnosis was 111 cells/μL (IQR; 62--221; Waddell *et al*. [@b123]). Excess risks standardised incidence ratio (SIR = 19.5, 95% CI: 6.3--45.5) have also been observed among a cohort of kidney transplant recipients in Australia suggesting that immune suppression from other causes may play a role (Vajdic *et al*. [@b116]).

HAART does not reduce the incidence of SCCC according to data from the US HIV/AIDS Cancer Match (HACM) Study (Guech-Ongey *et al*. [@b36]) which compared SIRs in the pre-HAART and HAART eras among 491 048 adults aged ≥15 years with HIV/AIDS diagnosed from 1980 to 2004. The SIRs here estimate the excess risk of SCCC attributable to HIV/AIDS compared with a population with negligible HIV/AIDS prevalence and were similar at 12.0 (95% CI: 5.5--22.8) and 12.6 (95% CI: 4.6--27.4) in the pre- and post-HAART eras, respectively (*P* = 0.79). There is, however, a case report of ART causing tumour regression in an otherwise inoperable case (Holkar *et al*. [@b43]).

### Human papilloma virus

The relationship between human papilloma virus (HPV) and OSSN is rather controversial with variable results. (Tulvatana [@b112]; Moubayed *et al*. [@b72]; Sen *et al*. [@b96]; de Koning *et al*. [@b20]; Guthoff *et al*. [@b38]; Simbiri *et al*. [@b98]; Yu *et al*. [@b128]). A review of 12 case series and 17 case--control studies concluded that there was no causal association between mucosal HPV types and OSSN while the role of cutaneous types was uncertain (de Koning *et al*. [@b20]). The studies included used different methods for testing of HPV (including PCR and serology), and different HPV types were examined. Conversely, a random-effects meta-analysis of various case--control studies shows that OSSN is associated with HPV infection in sub-Saharan Africa (pooled OR = 2.64, 95% CI: 1.27--5.49) and worldwide (pooled OR = 4.00, 95% CI: 2.11--7.57; Figure[6](#fig06){ref-type="fig"}). The prevalence of HPV in OSSN ranges from 0% to 100% depending on geographical region with subtypes HPV18 and HPV16 being the most common (Table [8](#tbl8){ref-type="table"}; di Girolamo [@b24]). Most African studies report prevalence of 75--85% (Ateenyi-Agaba *et al*. [@b5]; Simbiri *et al*. [@b98]; Yu *et al*. [@b128]). HPV is more commonly isolated in OSSN than pterygium -- on average, considering studies from different regions of the world, 33.8% of OSSN lesions and 18.6% of pterygia are HPV positive (di Girolamo [@b24]). There may be a true geographical variation in the prevalence of HPV in OSSN.

![Meta-analysis of case-control studies of human papilloma virus (HPV) infection in ocular surface squamous neoplasia (OSSN) (random effects).](tmi0018-1424-f6){#fig06}

###### 

Characteristics of case--control studies included in the meta-analysis of HIV as a risk factor of ocular surface squamous neoplasia (OSSN)

  Study period (ref.), Country                      Cases                                                                                                                                                                                                 Controls
  ------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1989--1990 (Kestelyn *et al*. [@b50]), Rwanda     11 patients with clinical evidence of conjunctival dysplasia or malignancy seen at Centre Hospitalier de Kigali                                                                                       22 controls. 2 controls per case from the same area matched for age and sex within 5 years. Referrals from elsewhere were excluded
  1990--1991 (Ateenyi-Agaba [@b3]), Uganda          48 patients with conjunctival growths who presented to the eye clinic at Mulago Hospital, Kampala                                                                                                     48 patients matched for age and sex attending the same eye clinic with other eye diseases
  1993--1994 (Waddell *et al*. [@b121]), Uganda     38 patients in seven countrywide eye clinics including New Mulago Hospital, Kampala who had suspicious conjunctival lesions had excision biopsy of the lesion                                         76 controls. 2 controls per case matched for age and sex. 16 Controls were patients in the eye clinic without neoplasia or clinical features of HIV disease; the remainder were general (non-eye clinic) anonymous outpatients at the same health units
  1993--1995 (Porges & Groisman [@b89]), Zimbabwe   13 cases from patients who underwent excisional biopsy for conjunctival lesions at Bindura Provincial Hospital (Mashonaland Central, Zimbabwe)                                                        7 controls. Patients were from the same group as cases but had benign lesions on histology
  1994--1998 (Newton *et al*. [@b78]), Uganda       22 cases. Patients aged \>15 years with a provisional diagnosis of cancer from all wards and out-patient clinics of the 4 main hospitals in Kampala: Mulago, Nsambya, Mengo and Rubaga                112 controls. 93 patients with tumours not suspected to be of infectious aetiology and 19 with non-malignant conditions
  2001--2005 (Waddell *et al*. [@b124]), Uganda     318 cases recruited from country-wide ophthalmology clinics in Uganda. Anyone with a suspected OSSN was offered surgical treatment and histology, together with enrolment into a case-control study   762 controls were recruited from 2 sources. The first group comprised patients attending the ophthalmology clinics with concerns or conditions other than OSSN. This group also included those individuals who were originally recruited as cases, but where histology subsequently revealed another diagnosis. The second group comprised people who were recruited through the voluntary HIV counselling and testing (VCT) service

###### 

Studies on the prevalence and subtypes of human papilloma virus (HPV) in ocular surface squamous neoplasia (OSSN)

  Lead author (ref.)                             Year   Country                                        Disease included              Sample size   Diagnostic method     HPV prevalence (%)   HPV subtypes found          Tissue used
  ---------------------------------------------- ------ ---------------------------------------------- ----------------------------- ------------- --------------------- -------------------- --------------------------- ---------------------------------------------------------------------------
  *Africa*                                                                                                                                                                                                                
  Ateenyi-Agaba (Ateenyi-Agaba *et al*. [@b4])   2004   Uganda                                         SCC                           21            PCR                   86                   14, 27, 37, 38              Fresh frozen tissue shipped to France
  Simbiri (Simbiri *et al*. [@b98])              2010   Botswana                                       OSSN                          30            PCR                   72                   6, 11, 16, 18, 31, 33       Fresh tissue shipped in tissue transport medium to USA
  DNA sequencing                                 100    21 subtypes[\*](#tf8-2){ref-type="table-fn"}                                                                                                                      
  IHC                                            72     ?                                                                                                                                                                 
  ISH                                            61     ?                                                                                                                                                                 
  Waddell (Waddell *et al*. [@b122])             2003   Uganda                                         CIN I--III                    254           anti-HPV antibodies   15                   16                          Plasma shipped in dry ice to France
  Newton (Newton *et al*. [@b79])                2002   Uganda                                         SCC                           39            anti-HPV antibodies   36                   16, 18, 45                  Serum shipped in dry ice to France
  de Koning (de Koning *et al*. [@b20])          2008   Uganda                                         CIN I                         17            PCR                   47                   35% gen, 29% cut            Formalin-fixed paraffin-embedded tissue shipped overseas
  CIN II                                         18     56                                             50% gen, 28% cut                                                                                                   
  CIN III                                        22     45                                             27% gen, 23% cut                                                                                                   
  SCC                                            24     22                                             42% gen, 13% cut                                                                                                   
  Ateenyi-Agaba (Ateenyi-Agaba *et al*. [@b6])   2010   Uganda                                         SCC                           94            PCR                   45                   6.4% muc, 44.7% cut         Fresh frozen biopsies shipped to the Netherlands
  Dysplasia                                      39     41                                             7.7% muc, 41% cut                                                                                                  
  Tornesello (Tornesello *et al*. [@b109])       2006   Uganda                                         CIN I                         16            PCR                   31                   20, CJ198, indeterm         ?
  CIN II                                         18     33                                             18, 38, 100, DL473, PPHLIFR                                                                                        
  CIN III                                        23     13                                             18, 100                                                                                                            
  SCC                                            29     3                                              14, 20,CJ198                                                                                                       
  *North America*                                                                                                                                                                                                         
  Scott (Scott *et al*. [@b95])                  2002   USA                                            Dysplasia                     10            PCR                   100                  16, 18                      Formalin-fixed paraffin-embedded tissue
  Odrich (Odrich *et al*. [@b81])                1991   USA                                            SCC                           3             PCR                   100                  16                          ?
  McDonnell (McDonnell *et al*. [@b69])          1992   USA                                            OSSN                          42            PCR/DB                88                   16                          Formalin-fixed paraffin-embedded tissue
  Lauer (Lauer *et al*. [@b53])                  1990   USA                                            OSSN                          5             PCR                   80                   16, 18                      ?
  Dushku (Dushku *et al*. [@b27])                1999   USA                                            OSSN                          8             PCR                   0                    Nil detected                Fresh tissue
  *Asia*                                                                                                                                                                                                                  
  Kuo (Kuo *et al*. [@b52])                      2006   Taiwan                                         Dysplasia                     9             PCR                   100                  6, 11, 16, 18, 33, 58, 72   Formalin-fixed paraffin-embedded tissue
  Karcioglu (Karcioglu & Issa [@b49])            1997   Saudi Arabia                                   CIS/SCC                       45            PCR                   56                   16, 18                      Formalin-fixed paraffin-embedded tissue
  Nakamura (Nakamura *et al*. [@b74])            1997   Japan                                          OSSN                          8             PCR/IHC               50                   16, 18                      Formalin-fixed paraffin-embedded tissue
  Saegusa (Saegusa *et al*. [@b93])              1995   Japan                                          OSSN                          8             PCR/ISH               38                   16                          Formalin-fixed paraffin-embedded tissue
  Toth (Toth *et al*. [@b110])                   2000   Saudi Arabia                                   SCC                           16            PCR                   25                   16                          Formalin-fixed paraffin-embedded tissue
  Manderwad (Manderwad *et al*. [@b63])          2009   India                                          OSSN                          48            PCR/ISH-CARD          0                    Nil detected                Formalin-fixed paraffin-embedded tissue supplemented with 7 fresh tissues
  Eng (Eng *et al*. [@b29])                      2002   Taiwan                                         OSSN                          20            PCR                   0                    Nil detected                Formalin-fixed paraffin-embedded tissue
  Tulvatana (Tulvatana [@b112])                  2003   Thailand                                       OSSN                          30            PCR/DB                0                    Nil detected                Formalin-fixed paraffin-embedded tissue
  Sen (Sen *et al*. [@b96])                      2007   India                                          OSSN                          30            IHC                   0                    Nil detected                Formalin-fixed, paraffin-embedded tissue
  *Oceania*                                                                                                                                                                                                               
  Tabrizi (Tabrizi *et al*. [@b103])             1997   Australia                                      OSSN                          88            PCR                   39                   6, 11, 13, 16, 18           Formalin-fixed paraffin-embedded tissue
  *Europe*                                                                                                                                                                                                                
  Auw-Haedrich (Auw-Haedrich *et al*. [@b7])     2008   Germany                                        Dysplasia                     12            PCR                   17                   16                          Freshly prepared formalin-fixed paraffin-embedded tissue
  Toth (Toth *et al*. [@b110])                   2000   Hungary                                        SCC                           7             PCR                   14                   18                          Formalin-fixed paraffin-embedded tissue
  Reszec(Reszec & Sulkowski [@b92])              2005   Poland                                         SCC                           11                                  9                    16, 18                      ?
  Guthoff (Guthoff *et al*. [@b38])              2009   Germany                                        OSSN                          31            PCR/IHC               0                    Nil detected                Formalin-fixed paraffin-embedded tissue
  Tuppurainen (Tuppurainen *et al*. [@b114])     1992   Finland                                        CIS/SCC                       4             PCR                   0                    Nil detected                ?

? -- means unclear or not mentioned.

The 21 subtypes were HPV types 1, 3, 7, 11, 13, 16, 18, 29, 39, 40, 43, 45, 59, 61, 68, 70, 77, 85, 89, 91, 97.

Differences in HPV prevalence in OSSN may be influenced by patient selection, sample handling in the operating theatre, preparation, storage, overseas shipping and the detection method. Variations may also be due to different testing methodology and the specific HPV types tested for. Most existing molecular diagnostic tests applied in OSSN testing for HPV were developed for cervical tissue testing. The sensitivity and specificity of various polymerase chain reaction (PCR) tests varies and may be influenced by various factors including the PCR design (nested, broad spectrum or type-specific), size of amplified product and choice of polymerase used (Munoz *et al*. [@b73]; Mesher *et al*. [@b71]). Detection of E6/E7 mRNA transcripts by quantitative reverse transcriptase--PCR (qRT-PCR) has been proposed as the gold standard for HPV testing (Smeets *et al*. [@b99]). However, RNA is unstable limiting this test to fresh frozen tissue (Kim *et al*. [@b51]). Testing for HPV DNA by PCR from paraffin-embedded archived tumour blocks may be complicated by contamination between samples at the time of initial tissue sectioning for DNA harvest (Boyd *et al*. [@b11]; Iftner & Villa [@b45]).

Generally, only a limited subset of HPV types has been investigated among OSSN cases. There are 170 genotypes of HPV described to date, which are broadly subdivided into cutaneous and mucosal types (de Villiers [@b23]). There are conflicting reports on which of these two are more commonly associated with OSSN. One study conducted in Uganda reported that among OSSN cases, the prevalence of mucosal types was higher than cutaneous types (38% *vs*. 22%) while from another study in the same population, the prevalence of cutaneous types was higher than mucosal types (43.6% *vs*. 6.8%; Table [8](#tbl8){ref-type="table"}; de Koning *et al*. [@b20]; Ateenyi-Agaba *et al*. [@b6]). Multiple HPV types have been found in individual patients with OSSN tumours. One Ugandan study reported multiple HPV types in 57.1% of SCCC and 75% of dysplasia cases by PCR (Ateenyi-Agaba *et al*. [@b6]). In Botswana, multiple HPV types were identified in all OSSN and all pterygium specimens by DNA sequencing (Simbiri *et al*. [@b98]). The HPV types found by sequencing ranged from 4 to 21 types per sample. The same study also described co-infection with multiple other viral types per individual in 17 of 18 (94%) histologically proven OSSN specimens by PCR; 83% were positive for Epstein--Barr virus (EBV), 72% were HPV positive, 67% were Kaposi\'s sarcoma-associated herpesvirus (KSHV) positive, 67% were herpes simplex virus (HSV-1/2) positive and 56% were cytomegalovirus (CMV) positive. All the pterygium specimens from that study similarly had multiple viruses; 75% were positive for each of EBV, KSHV, CMV and HSV while 50% were HPV positive. The proportion of HPV infection in this series was much higher than any other studies in the region have reported raising the question whether this could be due to the methodology used.

The mechanism by which HPV is associated with OSSN is unknown. HPV is associated with causation of metaplasia in squamocolumnar epithelial transition zones such as the corneoscleral limbus and eyelid skin of the eye, the cervix and anus where there is active cell turnover and continuous cell division to replace desquamated cells (Chow *et al*. [@b15]). HPV also promotes degradation of the p53 gene (Scheffner *et al*. [@b94]).

The epidemiology of OSSN is closely related to that of cervical cancer with respect to high incidence in Africa and the association with HIV and HPV mainly types 18 and 16 (Sun *et al*. [@b102]; Clifford *et al*. [@b16]; Stanley [@b101]). A meta-analysis of HPV prevalence reports worldwide shows that Africa has the highest adjusted prevalence (22.1%; 95% CI: 20.9--23.4%) among women with cytologically normal cervical pap smears using PCR-based or high-risk Hybrid Capture 2 (HC-2) technology to detect HPV DNA (de Sanjose *et al*. [@b21]). Whether vaccination against HPV may help to reduce the incidence of OSSN remains to be seen (Hughes *et al*. [@b44]).

### Occupation

Outdoor occupations have been associated with OSSN, probably related to UV solar radiation exposure. In Uganda, those with outdoor occupations had an OR of 1.7 (95% CI: 1.1--2.6) compared to those with indoor occupations (Waddell *et al*. [@b124]). Another in Uganda reported that 74% of 133 patients with SCCC or dysplasia had outdoor occupations (Ateenyi-Agaba *et al*. [@b6]). In Japan, exposure to petroleum products was also described as a risk factor for conjunctival intraepithelial neoplasia (synonym of OSSN) in a small age--sex-matched case--control study (Napora *et al*. [@b75]). Exposure to smoke from burning wood in the kitchen was described as a risk factor for cervical cancer among HPV-infected women in Honduras (Velema *et al*. [@b117]).

### Cigarette smoking

Cigarette smoking is implicated in other squamous cell cancers (Haverkos [@b40]). There is, however, evidence of no effect from smoking on OSSN in Africa. In Uganda, two case--control studies showed that current smokers were not at a significantly higher risk for OSSN than non-smokers (Waddell *et al*. [@b124]; Ateenyi-Agaba *et al*. [@b6]; pooled OR = 1.40; 95% CI: 0.94--2.09; Figure[7](#fig07){ref-type="fig"}). In a Nigerian series of 37 SCCC cases, only two patients (5.4%) had a history of cigarette smoking (Ogun *et al*. [@b82]) while in a series from Australia, 5 of 11 cases of SCCC (45%) were smokers (McKelvie [@b70]).

![Meta-analysis of case-control studies in Uganda on cigarette smoking and ocular surface squamous neoplasia (OSSN) in Africa (fixed effect).](tmi0018-1424-f7){#fig07}

### Allergy

There is little evidence that allergic conjunctivitis is a risk factor. Among 215 SCCC cases in Tanzania, 1.9% had allergic conjunctivitis (Poole [@b88]). In Rwanda, allergic conjunctivitis was found in 4% of children and was responsible for 3--6% of hospital visits of all ages (de Smedt *et al*. [@b22]). In a case--control study in Uganda, none of the cases of OSSN had a history of allergic eye disease (Waddell *et al*. [@b124]). However, a case series of SCCC from Germany reported that 6/10 cases had atopic eczema, so this may be of more importance in temperate climates (Heinz *et al*. [@b41]).

### Xeroderma pigmentosum

Xeroderma pigmentosum (XP), a rare, inherited skin disease characterised by high sensitivity to UV damage is associated with a high prevalence (40%) of specific mutations of the TP53 tumour suppressor gene (Dumaz *et al*. [@b26]). Over a 25-year period in Zimbabwe, in a series of 12 cases, 2 had SCCC while the rest had SCC of the skin, lip or tongue (Chidzonga *et al*. [@b13]). From a series of 7 XP cases in India, 6 of the 14 eyes (42.9%) had invasive SCC and eight eyes (57.1%) had CIN (Gupta *et al*. [@b37]). A larger series of 32 cases in France found that 59% of them had ocular and periocular malignancies (Touzri *et al*. [@b111]).

### Vitamin A deficiency

The importance of vitamin A in maintaining the health of the ocular surface is well known, but the role of vitamin A deficiency in OSSN has not been established. Deficiency of vitamin A induces keratinisation of the ocular surface (Beitch [@b10]; Pfister & Renner [@b86]). Keratinisation is commonly observed as leucoplakia in OSSN lesions (Figure[1](#fig01){ref-type="fig"}). There is a synergistic interaction between vitamin A and zinc in maintenance of the corneal and conjunctival epithelium (Kanazawa *et al*. [@b47]). In South Africa, it was shown that 54% of HIV-infected adults are deficient in vitamin A (plasma retinol \<1.05 μ[m]{.smallcaps}) and 33% deficient in zinc (\<10.7 μ[m]{.smallcaps}; Visser *et al*. [@b119]). In Ethiopia, 53% of HIV-infected adults were deficient in vitamin A (Fufa *et al*. [@b30]). As most patients with OSSN are also HIV-infected, it is plausible that vitamin A deficiency contributes to the aetiology.

### Other risk factors

There is limited evidence of a role for exposure to dust, ocular trauma and pre-existing benign conjunctival lesions such as pterygia and pingueculae (Templeton [@b105]; Margo & Groden [@b64]; Waddell *et al*. [@b124]).

### Protective factors

One of the Ugandan case--control studies found that some factors are associated with a lower risk for SCCC such as higher personal income (adjusted OR = 0.4, 95% CI: 0.3--0.7) and decreasing age at leaving home (*P* = 0.05), perhaps reflecting less exposure to sunlight consequent to rural-to-urban migration (Newton *et al*. [@b79]).

Aetiological model of OSSN
--------------------------

Various models have been proposed to simultaneously address the role of two or more risk factors in cancer causation within hierarchical levels (Victora *et al*. [@b118]). Most such models focus on social and environmental hypothesis but do not incorporate biological factors. A recently proposed framework called Multi-level Biological And Social Integrative Construct (MBASIC) includes biological factors together with macro-environmental and individual level factors (Lynch & Rebbeck [@b59]). Using the existing evidence reviewed in this article, we propose an aetiological model that might explain how the risk factors discussed may be involved development of OSSN (Figure[8](#fig08){ref-type="fig"}).

![An aetiological model illustrating how ocular surface squamous neoplasia (OSSN) might develop. MMPs, matrix metalloproteinases; TIMPs, tissue inhibitors of metalloproteinases.](tmi0018-1424-f8){#fig08}

Conclusions
===========

OSSN is a disease of increasing importance in Africa. A triad of ultraviolet solar radiation, HIV and HPV form the major risk factors and this may explain the high incidence rates in Africa. There is evidence from case--control studies that exposure to UV radiation, outdoor occupations -- perhaps due to exposure to sunlight, HIV and HPV infection are associated with a higher risk for OSSN. These studies also show no evidence of effect of cigarette smoking. Dust, ocular trauma and pre-existing benign conjunctival tumours may play a role. Although mentioned in the literature, the effect of atopy and xeroderma pigmentosa is unclear. The effect of vitamin A deficiency has not been examined in case--control studies.

The highest incidence of OSSN is found in Africa, where males and females are equally affected, unlike other continents where male disease predominates. This probably reflects that African women have increased risk due to their higher prevalence of HIV and HPV infections. As people with HIV are living longer, and given no evidence that ART reduces risk of OSSN, one could expect incidence of OSSN to increase in Africa in coming years.

Currently, the best available options for OSSN control remain early detection and effective treatment. However, there are no early non-invasive diagnostic methods in use and no trial evidence to guide treatment. OSSN is currently largely neglected by both eye and HIV care programmes. Eye care programmes prioritise preventable blindness while OSSN often in early stages does not affect vision. OSSN may, however, lead to facial disfigurement and death in late stages. In Africa, a key research question is whether scale-up of ART and HPV vaccination will impact on OSSN.
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